TG Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
TG Therapeutics has a total shareholder equity of $160.1M and total debt of $101.6M, which brings its debt-to-equity ratio to 63.5%. Its total assets and total liabilities are $373.3M and $213.2M respectively. TG Therapeutics's EBIT is $48.4M making its interest coverage ratio 4. It has cash and short-term investments of $209.8M.
Key information
63.5%
Debt to equity ratio
US$101.65m
Debt
Interest coverage ratio | 4x |
Cash | US$209.79m |
Equity | US$160.11m |
Total liabilities | US$213.21m |
Total assets | US$373.32m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0VGI's short term assets ($360.6M) exceed its short term liabilities ($99.7M).
Long Term Liabilities: 0VGI's short term assets ($360.6M) exceed its long term liabilities ($113.5M).
Debt to Equity History and Analysis
Debt Level: 0VGI has more cash than its total debt.
Reducing Debt: 0VGI's debt to equity ratio has reduced from 147.6% to 63.5% over the past 5 years.
Debt Coverage: 0VGI's debt is not well covered by operating cash flow (20%).
Interest Coverage: 0VGI's interest payments on its debt are well covered by EBIT (4x coverage).